keynote-564: pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with...
Published 3 years ago • 382 plays • Length 5:33Download video MP4
Download video MP3
Similar videos
-
1:50
keynote 564 update
-
9:29
keynote-564 study
-
10:51
asco gu24 special: assoc. prof. barata discusses the results of keynote-564 and checkmate-914
-
1:00
adjuvant pembrolizumab in kidney cancer from keynote 564
-
2:53
adjuvant pembrolizumab vs placebo for dfs benefit in rcc
-
2:22
adjuvant pembrolizumab and survival in renal-cell carcinoma | nejm
-
3:34
neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in os
-
9:59
gs1-01: "phase 3 study of pembrolizumab chemotherapy vs placebo chemotherapy as neoadjuvant..."
-
6:41
pembrolizumab as adjuvant therapy for patients with renal cell carcinoma
-
0:35
the latest developments in adjuvant therapy for rcc
-
5:51
how does keynote-564 open the door for new adjuvant approaches?
-
1:00
the keynote 564 trial - the key to adjuvant therapy in rcc
-
3:01
a phase iii trial of pembrolizumab as adjuvant treatment for renal cell carcinoma
-
1:03
potential of adjuvant therapy for rcc
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
0:43
dr. rini on adjuvant immunotherapy in renal cell carcinoma
-
3:31
fda d.i.s.c.o. burst edition: fda approval of keytruda (pembrolizumab) for the adjuvant treatment...
-
6:43
adjuvant nivolumab ipilimumab vs placebo in localized renal cell carcinoma | dr. suparna rao
-
4:16
kidney cancer treatment options